CARsgen Therapeutics-B (02171): Research Findings Update on In Vivo CAR-T Candidate Product CT1182
Zhitong Finance APP news, CARsgen Therapeutics-B (02171) announced preliminary clinical data for CT1182 (KJ-C2529), an in vivo CAR-T candidate targeting CD19/CD20 developed based on the Company's self-developed CARvivo platform, for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data show that this in vivo CAR-T candidate has preliminary favorable safety and encouraging efficacy signals.
Latest
11 m ago

